AllovirInc Stock Today


USD 7.15  0.04  0.56%   

Market Performance
0 of 100
Odds Of Distress
Less than 24
AllovirInc is selling at 7.15 as of the 7th of December 2022; that is 0.56 percent up since the beginning of the trading day. The stock's lowest day price was 6.99. AllovirInc has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for AllovirInc are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 8th of September 2022 and ending today, the 7th of December 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
30th of July 2020
Health Care
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell therapies to prevent and treat devastating viral-associated diseases. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts. The company has 93.16 M outstanding shares of which 4.27 M shares are presently shorted by private and institutional investors with about 13.0 trading days to cover. More on AllovirInc

Moving against AllovirInc

-0.56KOCoca-Cola Aggressive PushPairCorr
-0.54BMYBristol-Myers Squibb Aggressive PushPairCorr
-0.53MMM3M Company Sell-off TrendPairCorr
-0.52CAHCardinal Health Sell-off TrendPairCorr
Follow Valuation Odds of Bankruptcy
Check how we calculate scores

AllovirInc Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. AllovirInc's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding AllovirInc or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
AllovirInc generated a negative expected return over the last 90 days
AllovirInc has high historical volatility and very poor performance
Net Loss for the year was (171.96 M) with profit before overhead, payroll, taxes, and interest of 165 K.
AllovirInc currently holds about 172.67 M in cash with (106.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Roughly 50.0% of the company shares are held by company insiders
Latest headline from MacroaxisInsider: Sale by Van Beek Jeroen B of 16074 shares of AllovirInc
Acting President and CEOAssaf Katan
Fama & French Classification
Average Analyst Recommendation
Analysts covering AllovirInc report their recommendations after researching AllovirInc's financial statements, talking to executives and customers, or listening in on AllovirInc's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering AllovirInc. The AllovirInc consensus assessment is calculated by taking the average forecast from all of the analysts covering AllovirInc.
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of AllovirInc's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
AllovirInc (ALVR) is traded on NASDAQ Exchange in USA and employs 107 people. AllovirInc is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 672.64 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate AllovirInc's market, we take the total number of its shares issued and multiply it by AllovirInc's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. AllovirInc conducts business under Biotechnology sector and is part of Health Care industry. The entity has 93.16 M outstanding shares of which 4.27 M shares are presently shorted by private and institutional investors with about 13.0 trading days to cover. AllovirInc currently holds about 172.67 M in cash with (106.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.91.
Check AllovirInc Probability Of Bankruptcy
AllovirInc retains a total of 93.16 Million outstanding shares. AllovirInc retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check AllovirInc Ownership Details

AllovirInc Stock Price Odds Analysis

In regard to a normal probability distribution, the odds of AllovirInc jumping above the current price in 90 days from now is about 83.51%. The AllovirInc probability density function shows the probability of AllovirInc stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.7098. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, AllovirInc will likely underperform. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. AllovirInc is significantly underperforming NYSE Composite.
  Odds Below 7.15HorizonTargetOdds Above 7.15
16.40%90 days
Based on a normal probability distribution, the odds of AllovirInc to move above the current price in 90 days from now is about 83.51 (This AllovirInc probability density function shows the probability of AllovirInc Stock to fall within a particular range of prices over 90 days) .

AllovirInc Risk Profiles

Investors will always prefer to have the highest possible return on investment while minimizing volatility. AllovirInc market risk premium is the additional return an investor will receive from holding AllovirInc long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in AllovirInc. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although AllovirInc's alpha and beta are two of the key measurements used to evaluate AllovirInc's performance over the market, the standard measures of volatility play an important role as well.

AllovirInc Stock Against Markets

Picking the right benchmark for AllovirInc stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in AllovirInc stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for AllovirInc is critical whether you are bullish or bearish towards AllovirInc at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in AllovirInc without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now


Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

AllovirInc Corporate Executives

Elected by the shareholders, the AllovirInc's board of directors comprises two types of representatives: AllovirInc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of AllovirInc. The board's role is to monitor AllovirInc's management team and ensure that shareholders' interests are well served. AllovirInc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, AllovirInc's outside directors are responsible for providing unbiased perspectives on the board's policies.

Invested in AllovirInc?

The danger of trading AllovirInc is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AllovirInc is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AllovirInc. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AllovirInc is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please continue to Trending Equities. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for analysis

When running AllovirInc price analysis, check to measure AllovirInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AllovirInc is operating at the current time. Most of AllovirInc's value examination focuses on studying past and present price action to predict the probability of AllovirInc's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AllovirInc's price. Additionally, you may evaluate how the addition of AllovirInc to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Is AllovirInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AllovirInc. If investors know AllovirInc will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AllovirInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
672.6 M
Return On Assets
Return On Equity
The market value of AllovirInc is measured differently than its book value, which is the value of AllovirInc that is recorded on the company's balance sheet. Investors also form their own opinion of AllovirInc's value that differs from its market value or its book value, called intrinsic value, which is AllovirInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AllovirInc's market value can be influenced by many factors that don't directly affect AllovirInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AllovirInc's value and its price as these two are different measures arrived at by different means. Investors typically determine AllovirInc value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AllovirInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.